Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Menadione | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione. |
| Tranexamic acid | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid. |
| Aminocaproic acid | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminocaproic acid. |
| Aprotinin | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aprotinin. |
| Hydrogen peroxide | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Hydrogen peroxide. |
| Aminomethylbenzoic acid | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminomethylbenzoic acid. |
| Camostat | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Camostat. |
| Menadione bisulfite | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione bisulfite. |
| Fibrinogen human | The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor. |
| Antihemophilic factor, human recombinant | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor, human recombinant. |
| Coagulation factor VIIa Recombinant Human | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human. |
| Coagulation Factor IX (Recombinant) | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX (Recombinant). |
| Calcium | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium. |
| Pantothenic acid | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Pantothenic acid. |
| Formic acid | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Formic acid. |
| Platelet Activating Factor | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Platelet Activating Factor. |
| Turoctocog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa. |
| Catridecacog | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Catridecacog. |
| Antihemophilic factor (recombinant), PEGylated | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated. |
| Prothrombin | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Prothrombin. |
| Factor IX Complex (Human) | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human). |
| Susoctocog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Susoctocog alfa. |
| Eftrenonacog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Eftrenonacog alfa. |
| Rusalatide acetate | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Rusalatide acetate. |
| Vatreptacog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Vatreptacog alfa. |
| Factor XIII (human) | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human). |
| Von Willebrand factor human | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Von Willebrand factor human. |
| Coagulation factor X human | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor X human. |
| Coagulation factor VII human | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VII human. |
| Anti-inhibitor coagulant complex | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Coagulation Factor IX Human | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX Human. |
| Antihemophilic factor human | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor human. |
| Kallidinogenase | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Kallidinogenase. |
| Trenonacog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Trenonacog alfa. |
| Albutrepenonacog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Albutrepenonacog alfa. |
| Emicizumab | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Emicizumab. |
| Nonacog beta pegol | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Nonacog beta pegol. |
| Moroctocog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Moroctocog alfa. |
| Beroctocog alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Beroctocog alfa. |
| Andexanet alfa | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Andexanet alfa. |
| Calcium cation | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium cation. |
| Damoctocog alfa pegol | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Damoctocog alfa pegol. |
| Turoctocog alfa pegol | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa pegol. |
| Alteplase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Alteplase. |
| Urokinase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Urokinase. |
| Reteplase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Reteplase. |
| Anistreplase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Anistreplase. |
| Tenecteplase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Tenecteplase. |
| Streptokinase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Streptokinase. |
| Lanoteplase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Lanoteplase. |
| Amediplase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Amediplase. |
| Saruplase | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Saruplase. |
| Protein S human | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Protein S human. |
| Rurioctocog alfa pegol | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Rurioctocog alfa pegol. |
| Etranacogene dezaparvovec | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Etranacogene dezaparvovec. |